Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Patient Square Capital LP’s 10th Largest Position

Patient Square Capital LP boosted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 100.0% during the 4th quarter, Holdings Channel reports. The firm owned 470,919 shares of the biopharmaceutical company’s stock after buying an additional 235,421 shares during the period. Ocular Therapeutix comprises about 1.5% of Patient Square Capital LP’s portfolio, making the stock its 10th biggest holding. Patient Square Capital LP’s holdings in Ocular Therapeutix were worth $4,022,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix during the 4th quarter valued at approximately $1,722,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Ocular Therapeutix by 1.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock worth $9,663,000 after buying an additional 21,025 shares in the last quarter. Barclays PLC boosted its position in shares of Ocular Therapeutix by 37.1% during the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock worth $4,451,000 after acquiring an additional 138,441 shares during the last quarter. RoundAngle Advisors LLC bought a new position in shares of Ocular Therapeutix during the fourth quarter worth $1,695,000. Finally, Tower Research Capital LLC TRC grew its stake in Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 8,446 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Stock Down 5.3%

NASDAQ:OCUL opened at $7.00 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a 1-year low of $4.79 and a 1-year high of $11.78. The company has a 50-day moving average of $7.46 and a 200 day moving average of $8.23. The firm has a market cap of $1.12 billion, a PE ratio of -5.30 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on OCUL. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair started coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an “outperform” rating on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Needham & Company LLC reduced their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Ocular Therapeutix has an average rating of “Moderate Buy” and an average target price of $16.25.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.